Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

re performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...LLEGE PARK, Md., Nov. 25 /PRNewswire-USNewswire/ -... a shaving cream-like foam that stops severe bleed...sing Security Idea category of the Global Security... ,, Selected from more than 100 entries from ar...ntion at the GSC Security Summit conference held a...
(Date:11/25/2009)... HARBIN, China, Nov. 25 /PRNewswire-Asia-First...ne Medical" or "the Company") (Nasdaq: CSKI ), a,...veloping and producing,over-the-counter drugs in t...nced that the Company recently passed the Chinese ...al and Biological Products ("ICPBP") examination,f...
(Date:11/25/2009)... CITY, Calif., Nov. 25 A...ompany manufacturing point-of-care blood analysis ...rman and chief executive officer, will present at ...ce on Wednesday, December 2, 2009 at 2:00 p.m. ET....e Hotel in New York City. ,, About Abaxis ,...
Breaking Medicine Technology:Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Plastics chemical retards growth function of adult reproductive cells 9165 1Plastics chemical retards growth function of adult reproductive cells 9165 2Plastics chemical retards growth function of adult reproductive cells 9165 3New iPhone Application for Anesthesiologists 51079 1New iPhone Application for Anesthesiologists 51079 2AMDL Inc Introduces New Brand Name for Its DR 70 28FDP 29 In Vitro Diagnostic Cancer Test 51075 1AMDL Inc Introduces New Brand Name for Its DR 70 28FDP 29 In Vitro Diagnostic Cancer Test 51075 2AMDL Inc Introduces New Brand Name for Its DR 70 28FDP 29 In Vitro Diagnostic Cancer Test 51075 3AMDL Inc Introduces New Brand Name for Its DR 70 28FDP 29 In Vitro Diagnostic Cancer Test 51075 4
...China, Sept. 3 Simcere,Pharmaceutical Group (NYSE...randed generic pharmaceuticals and manufacturer of...so known as Endostar) in China,announced the inter...he request of the SFDA, Simcere initiated a Phase ...nd therapeutic efficacy of Endu, a modified,versio...
...rm follow up results from chronically infected Hep...tive data obtained earlier in 2008, - Study is t...ong-term antiviral effect of therapeutic He...trongly support move into a second generation, va... acting through TLR ...
Other Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4
(Date:11/27/2009)..., Mass., Nov. 27 GSI Gro...plier of precision technology products and semicon...ting of the Company,s shareholders has been schedu...tion of the meeting will be announced in due cours...a requisition notice from Stephen Bershad, a holde...
(Date:11/27/2009)...R, N.Y., Nov. 27 Preven...ider and fortunately every year, new vaccines are ...o all vaccines boost immunity for the same period ... shots, needed to keep immunity strong? ,, In...the American Academy of Pediatrics, Michael Pichic...
(Date:11/27/2009)...ng unprecedented medical, economic burdens, study ...News) -- The number of people with diabetes in the... 25 years, a new study predicts. , That would b...e with the disease, up from 23.7 million today. ,...with diabetes will triple, the study also warns, r...
(Date:11/27/2009)... Three new interactive anatomy education apps...ns expand health sciences learning opportunities f... Durham, NC (Vocus) November 27, 2009 -- Modalit...W), a division of Wolters Kluwer Health, today ann...tion apps on the App Store. Clemente’s Anato...
(Date:11/26/2009)...ig or too heavy can lead to strains or worse , ...re may be nothing wrong with stuffing your turkey ... same thing with your suitcase as you pack for hol...ted in 2008 in U.S. hospital emergency rooms, doct... for luggage-related injuries, such as muscle stra...
Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2
...er detection in line with the USA? , Prostate ca...vidence from ongoing trials. In many countries, ea...and opportunistic screening commences at 50 years,...their 40s was associated with subsequent prostate ...
...n, an antiemetic pharmaceutical drug (suitable for...entrations to those administered intravenously. Th... by specialists at the University Hospital of Nava...ceutical drug the efficacy of which against vomiti...
... Inc. (NYSE: WPI ), a leading specialty pharmaceu...Mark W. Durand, 48, as Senior,Vice President and C...on more than 20 years of executive,pharmaceutical ... be responsible for all of the Company,s financial...
...Y in Patients Ages 10 to 17 ...Nov. 15 ,Otsuka Pharmaceutical Co., Ltd. and Brist...y that the U.S. Food and Drug Administration (FDA)...prazole) for the treatment of pediatric patients (...
...ur Stop Vijay Singh Donates $50,000 To E...ford Financial Group CFO,James M. Davis and World ...homas from St. Jude and Laurie Tucker, Senior Vice...m the 2007 event,held this past June is the larges...
...ity , The prognosis for individuals with metast...gies to enhance the immune response have some clin...ccumb to progressive disease, in part because thei...elanoma cell lines and resected tumors by Norman S...
Other Medicine News:Health News:Should the UK lower the age for prostate cancer detection? 2Health News:Subcutaneous administration of an antiemetic for treating vomiting caused by chemotherapy 2Health News:Watson Names Mark Durand Chief Financial Officer 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 2Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 4Health News:JCI table of contents: Nov. 15, 2007 2Health News:JCI table of contents: Nov. 15, 2007 3Health News:JCI table of contents: Nov. 15, 2007 4Health News:JCI table of contents: Nov. 15, 2007 5Health News:JCI table of contents: Nov. 15, 2007 6
Clinical Xpert™ PDA Medical Reference and Decision-Support Tool
Diagnosoft HARP Cardiac MRI Tagging
VISULAS YAG III Combi Complete Laser Therapy System
...olter Monitoring System, equipped with the latest ...lysis algorithm, Heart Rate Variability analysis a...s with an Epicardia System in place have complete ...suit their needs, and managing their data. The Epi...
Medicine Products: